We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
AusPAR: Dupilumab
Australian Public Assessment Report
Device/Product Name
Dupixent
Active ingredients
Dupilumab
AusPAR Date
Published
Sponsor
Submission Number
PM-2020-03043-1-5
Submission Type
Extension of indications (new indication for a previously approved medication; and expansion of target population for an existing indication); and major variation (update to clinical trials section of the Product Information)
Decision
Approved